Neutropenia Is Not a Feature of Active Hepatitis B Infection

Definition of Active Hepatitis B (Guideline Consensus)

• The major international hepatitis B guidelines (EASL, AASLD, APASL, KASL) define the phases of chronic HBV infection solely on HBeAg status, HBV DNA levels, ALT elevation, and degree of liver inflammation, without reference to hematologic parameters such as neutrophil count. 1, 2, 3, 4
• Active hepatitis B is characterized by virologic and biochemical markers—high HBV DNA and elevated ALT—rather than any hematologic abnormality. 2
• Phase 2 (HBeAg‑positive chronic hepatitis B): high HBV DNA, markedly elevated ALT, moderate‑to‑severe liver inflammation, and accelerated fibrosis progression. 2
• Phase 4 (HBeAg‑negative chronic hepatitis B): moderate‑to‑high HBV DNA, elevated ALT, and active liver inflammation. 2

Frequency of Cirrhosis and Related Cytopenias in Chronic HBV

Neutropenia in the Context of Advanced Liver Disease

• In patients who have progressed to cirrhosis, neutropenia commonly arises secondary to hypersplenism and portal hypertension, reflecting a complication of end‑stage liver disease rather than active viral replication. 1, 5
• The presence of splenomegaly, thrombocytopenia, or other signs of portal hypertension should prompt evaluation for hypersplenism‑related neutropenia. 1

Clinical Approach When Neutropenia Is Detected in a Hepatitis B Patient

• Rule out advanced liver disease: assess for cirrhosis using non‑invasive fibrosis tests (e.g., FibroScan, APRI, FIB‑4) and imaging for splenomegaly. This aligns with guideline recommendations to evaluate cytopenias as potential markers of portal hypertension. 1
• Consider medication effects (e.g., pegylated interferon) as a separate cause of neutropenia; however, this is a drug‑related adverse event, not a disease‑intrinsic feature. (No citation provided for this statement in the source material.)

Chronic Hepatitis B Infection Phases and Management

Phases of Chronic HBV Infection

• The American Association for the Study of Liver Diseases describes Phase 1 of chronic HBV infection as HBeAg-positive, with very high levels of HBV DNA and normal ALT levels, characterized by minimal or no liver necroinflammation despite high viral load 6, 7
• Phase 2 is characterized by HBeAg positivity, high but relatively lower HBV DNA levels, and elevated ALT, with moderate to severe liver necroinflammation and accelerated fibrosis progression 6, 7
• The European Association for the Study of the Liver notes that Phase 3 is characterized by HBeAg negativity, anti-HBe positivity, low or undetectable HBV DNA, and normal ALT, with minimal hepatic necroinflammatory activity and low fibrosis 6, 7
• Phase 4 is characterized by HBeAg negativity, moderate to high HBV DNA levels, and elevated ALT, with active liver inflammation and risk of progressive disease 6, 8
• The American Association for the Study of Liver Diseases describes Phase 5 as HBsAg-clearance phase, characterized by HBsAg negativity, anti-HBc positivity, with or without anti-HBs, and undetectable HBV DNA in serum 8

Clinical Implications and Monitoring

• Regular monitoring of HBeAg, HBV DNA, and ALT is essential to determine the phase of infection and guide management decisions, according to the American Association for the Study of Liver Diseases 6
• The European Association for the Study of the Liver recommends monitoring frequency of every 3-6 months for liver function tests and HBV DNA in compensated patients 8
• Patients in phases 2 and 4 are candidates for antiviral therapy, as stated by the American Association for the Study of Liver Diseases 6, 8

Prognostic Factors

• High serum HBV DNA levels are associated with increased risk of cirrhosis, hepatocellular carcinoma, and liver-related mortality, according to the Clinical and Molecular Hepatology 8
• HBV genotype C is associated with lower rates of HBeAg seroconversion, more rapid progression to cirrhosis and HCC, as noted by the Clinical and Molecular Hepatology 8